Assessment of the analytical performances and sample stability on ST Genesia system using the STG-DrugScreen application.


Journal

Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508

Informations de publication

Date de publication:
08 2019
Historique:
received: 08 01 2019
accepted: 29 04 2019
pubmed: 8 5 2019
medline: 15 7 2020
entrez: 8 5 2019
Statut: ppublish

Résumé

Thrombin generation testing has been used to provide information on the coagulation phenotype of patients. The most used technique is the calibrated automated thrombogram (CAT) but it suffers from a lack of standardization, preventing its implementation in routine. The ST Genesia is a new analyzer designed to assess thrombin generation based on the same principle as the CAT. Unlike the CAT system, the ST Genesia is a benchtop, fully automated analyzer, able to perform the analyses individually and not by batch, with strict control of variables such as temperature and volumes, ensuring, theoretically, maximal reproducibility. This study aimed at assessing the performance of the STG-DrugScreen application on the ST Genesia analyzer. We also aimed at exploring stability of plasma samples after freezing and defining a reference normal range. Results demonstrated the excellent interexperiment precision of the ST Genesia and confirmed that the use of a reference plasma helps reducing the inter-experiments variability. Stability revealed that plasma samples are stable for at least 11 months at -70°C or lower, except for those containing low molecular weight heparins which have to be tested within 6 months. Freezing had no effect on the majority of thrombin generation parameters except on time to peak. Our results suggest an easy implementation of thrombin generation with the use of ST Genesia in the routine laboratory. This will facilitate the design of multicentric studies and enable the establishment of reliable and evidence-based thresholds, which may improve the management of patients treated with anticoagulants.

Sections du résumé

BACKGROUND
Thrombin generation testing has been used to provide information on the coagulation phenotype of patients. The most used technique is the calibrated automated thrombogram (CAT) but it suffers from a lack of standardization, preventing its implementation in routine. The ST Genesia is a new analyzer designed to assess thrombin generation based on the same principle as the CAT. Unlike the CAT system, the ST Genesia is a benchtop, fully automated analyzer, able to perform the analyses individually and not by batch, with strict control of variables such as temperature and volumes, ensuring, theoretically, maximal reproducibility.
OBJECTIVES
This study aimed at assessing the performance of the STG-DrugScreen application on the ST Genesia analyzer. We also aimed at exploring stability of plasma samples after freezing and defining a reference normal range.
RESULTS
Results demonstrated the excellent interexperiment precision of the ST Genesia and confirmed that the use of a reference plasma helps reducing the inter-experiments variability. Stability revealed that plasma samples are stable for at least 11 months at -70°C or lower, except for those containing low molecular weight heparins which have to be tested within 6 months. Freezing had no effect on the majority of thrombin generation parameters except on time to peak.
CONCLUSIONS
Our results suggest an easy implementation of thrombin generation with the use of ST Genesia in the routine laboratory. This will facilitate the design of multicentric studies and enable the establishment of reliable and evidence-based thresholds, which may improve the management of patients treated with anticoagulants.

Identifiants

pubmed: 31063645
doi: 10.1111/jth.14470
pmc: PMC6852561
pii: S1538-7836(22)14293-5
doi:

Substances chimiques

Anticoagulants 0
Biomarkers 0
Thrombin EC 3.4.21.5

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1273-1287

Informations de copyright

© 2019 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.

Références

Thromb Haemost. 2018 Jul;118(7):1203-1214
pubmed: 29890519
J Thromb Haemost. 2004 Aug;2(8):1395-401
pubmed: 15304046
Br J Haematol. 2007 Oct;139(2):303-9
pubmed: 17897307
Br J Haematol. 2015 Mar;168(5):719-27
pubmed: 25351814
J Thromb Haemost. 2007 Apr;5(4):886-8
pubmed: 17388799
Thromb Res. 2010 Apr;125(4):353-6
pubmed: 19942257
Thromb Haemost. 2012 May;107(5):985-97
pubmed: 22438031
J Thromb Thrombolysis. 2013 Feb;35(2):295-301
pubmed: 23242974
Clin Appl Thromb Hemost. 2010 Jun;16(3):313-7
pubmed: 19520682
Thromb Haemost. 2016 Jan;115(2):368-81
pubmed: 26510969
J Thromb Haemost. 2012 Mar;10(3):437-46
pubmed: 22212198
Haematologica. 2013 Apr;98(4):549-54
pubmed: 23100275
Thromb Res. 2012 Dec;130(6):929-34
pubmed: 22909826
Thromb J. 2018 Nov 12;16:28
pubmed: 30455596
Thromb Res. 2018 Nov;171:160-166
pubmed: 30316961
Thromb Haemost. 2008 Aug;100(2):362-4
pubmed: 18690360
Thromb Res. 2014 Jul;134(1):160-4
pubmed: 24792772
Thromb Res. 2011 Jan;127(1):29-34
pubmed: 20850172
Thromb Haemost. 2013 Aug;110(2):283-94
pubmed: 23765180
Pharmacol Res. 2009 Mar;59(3):160-6
pubmed: 19124079
Thromb Res. 2012 Dec;130(6):956-66
pubmed: 23006523
Pathophysiol Haemost Thromb. 2003;33(1):4-15
pubmed: 12853707
Thromb Res. 2015 Jul;136(1):125-30
pubmed: 25563679
Clin Chem. 2016 May;62(5):699-707
pubmed: 26955824
J Thromb Haemost. 2012 Dec;10(12):2544-54
pubmed: 23020632
Thromb Res. 2012 Nov;130(5):769-74
pubmed: 22261474
J Thromb Haemost. 2019 Aug;17(8):1273-1287
pubmed: 31063645
Anesthesiology. 2017 Nov;127(5):852-861
pubmed: 28857806
Thromb Haemost. 1986 Aug 20;56(1):9-17
pubmed: 2430342
J Clin Pathol. 1953 Feb;6(1):3-8
pubmed: 13034911
Blood Coagul Fibrinolysis. 2018 Mar;29(2):148-154
pubmed: 29176379
Semin Thromb Hemost. 2010 Oct;36(7):791-6
pubmed: 20979000
Anesthesiology. 2017 Nov;127(5):744-746
pubmed: 28857805
Thromb Res. 2015 Jul;136(1):139-43
pubmed: 25956288
Blood Coagul Fibrinolysis. 2001 Jun;12(4):229-36
pubmed: 11460005
Res Pract Thromb Haemost. 2017 Oct 16;2(1):42-48
pubmed: 30046705

Auteurs

Jonathan Douxfils (J)

Department of Pharmacy, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, University of Namur, Namur, Belgium.
Qualiblood s.a., Namur, Belgium.

Laure Morimont (L)

Department of Pharmacy, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, University of Namur, Namur, Belgium.

Céline Bouvy (C)

Qualiblood s.a., Namur, Belgium.

Marie de Saint-Hubert (M)

Department of Geriatric, CHU UCL Namur, Université catholique de Louvain, Yvoir, Belgium.

Bérangère Devalet (B)

Department of Hematology, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, CHU UCL Namur, Université catholique de Louvain, Yvoir, Belgium.

Célia Devroye (C)

Hematology Laboratory, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, CHU UCL Namur, Université catholique de Louvain, Yvoir, Belgium.

Anne-Sophie Dincq (AS)

Department of Anesthesiology, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, CHU UCL Namur, Université catholique de Louvain, Yvoir, Belgium.

Jean-Michel Dogné (JM)

Department of Pharmacy, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, University of Namur, Namur, Belgium.

Maïté Guldenpfennig (M)

Hematology Laboratory, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, CHU UCL Namur, Université catholique de Louvain, Yvoir, Belgium.

Justine Baudar (J)

Hematology Laboratory, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, CHU UCL Namur, Université catholique de Louvain, Yvoir, Belgium.

Anne-Sophie Larock (AS)

Department of Pharmacy, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, CHU UCL Namur, Université catholique de Louvain, Yvoir, Belgium.

Sarah Lessire (S)

Department of Anesthesiology, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, CHU UCL Namur, Université catholique de Louvain, Yvoir, Belgium.

François Mullier (F)

Hematology Laboratory, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, CHU UCL Namur, Université catholique de Louvain, Yvoir, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH